Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance

BACKGROUND: Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) approved for use in EGFR-mutant lung cancer. We examined its performance in the second/subsequent line after resistance to first- and second-generation (1/2G) EGFR-TKI. METHODS: We rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Jun, Tan, Sze Huey, Yin, Daniel Xing Cheng, Tran, Nguyen Tuan Anh, Tan, Gek San, Lai, Gillianne Geet Yi, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Rajasekaran, Tanujaa, Tan, Eng-Huat, Lim, Tony Kiat Hon, Tan, Daniel Shao-Weng, Lim, Darren Wan-Teck, Ng, Quan Sing, Tan, Wan Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183387/
https://www.ncbi.nlm.nih.gov/pubmed/37197627
http://dx.doi.org/10.21037/tlcr-22-661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183387/
https://www.ncbi.nlm.nih.gov/pubmed/37197627
http://dx.doi.org/10.21037/tlcr-22-661

Ejemplares similares